XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

NCT00386685 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: larotaxel (XRP9881)
DRUG: trastuzumab

Sponsor

Sanofi